The impact of disruptions caused by the COVID-19 pandemic on global polio eradication
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Centers for Disease Control and Prevention
- Bill and Melinda Gates Foundation (INV-009333)
- U.S. Department of Health and Human Services
This publication has 28 references indexed in Scilit:
- Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccineExpert Review of Vaccines, 2018
- Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated SubpopulationsRisk Analysis, 2018
- Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining SerotypesThe Journal of Infectious Diseases, 2017
- Poliovirus vaccination during the endgame: insights from integrated modelingExpert Review of Vaccines, 2017
- Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016MMWR. Morbidity and Mortality Weekly Report, 2016
- Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine useBMC Infectious Diseases, 2016
- Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessationBMC Infectious Diseases, 2016
- An economic analysis of poliovirus risk management policy options for 2013–2052BMC Infectious Diseases, 2015
- Modeling Population Immunity to Support Efforts to End the Transmission of Live PoliovirusesRisk Analysis, 2012
- Optimal vaccine stockpile design for an eradicated disease: Application to polioVaccine, 2010